Table 6. Results of identified economic evaluations for LVADs as destination therapy.

Reference	Result
Clegg et al., 2005 (5)	ICER “base-case scenario”: £170,616/QALY (0.6 QALYs gained and additional cost of £102,000 per patient) ICER “future scenario”: £44,339/QALY If 60% improvement in survival versus REMATCH trial and lower device cost of £35,000
Adang et al., 2006 (6)	ICER: ca.€112,000/QALY (1.07 QALYs gained and additional cost of €119,000 per patient)
Girling et al., 2007 (7)	LVAD therapy is extremely unlikely to be cost-effective at current UK QALY valuations of around £30,000 if the device costs as much as £60,000
Messori et al., 2009 (9)	Mean reimbursement base-case analysis: €82,426 (range, €0 to €250,000) Mean reimbursement in scenario with utility of 0.809: €66,683
Rogers et al., 2012 (10)	ICER: $198,184/QALY (1.5 QALYs gained and additional cost of $297,551) and $167,208/LYG (1,78 LYG and additional cost of $297,551)
Neyt et al., 2013 (11)	ICER: €107,600/QALY (95% CI, 66,700-181,100) (2.83 QALYs gained and additional cost of €299,100) and €94,100/LYG (95% CI, 59,100-160,100) (3.23 LYG and additional cost of €299,100)

ICER, Incremental cost-effectiveness ratios; QALYs, quality-adjusted life-years; LYG, life-years gained. Exchange rates January 9, 2014: US $1 = €0.736; £1 = €1.211 (source: www.xe.com).